[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630436":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":24,"locations":30,"responsibleParty":46,"collaborators":10,"id":49,"slug":10,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":10,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":10,"studyType":61,"phases":10,"briefSummary":62,"conditions":63,"keywords":10,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Sultan 1. Murat State Hospital","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment success group",null,"Patients who demonstrated a ≥50% reduction in the number of days of analgesic use for headache at the end of the second-month evaluation",[13],"Other: Treatment outcome",{"label":15,"type":10,"description":16,"interventionNames":17},"Treatment failure group","Patients who demonstrated a \\\u003C50% reduction in the number of days of analgesic use for headache at the end of the second-month evaluation",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"OTHER","Treatment outcome","Before the injection, patients will be evaluated for the number of headache days, headache severity, the number of days of analgesic use for headache, headache-related disability, pressure pain threshold over the bilateral greater occipital nerve, anxiety and depression scores, and sleep quality. At 1 and 2 months after the injection, they will be reassessed for the number of headache days, headache severity, and the number of days of analgesic use for headache. In addition, at 1 hour after the injection, the pain experienced during the injection procedure will be assessed.",[15,9],[25],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Alper Mengi, MD","CONTACT","+90 537 651 03 85","dralpmengi@gmail.com",[31],{"facility":5,"status":32,"city":33,"state":10,"zip":34,"country":35,"countryCode":10,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"RECRUITING","Edirne","22030","Turkey (Türkiye)",{"type":37,"coordinates":38},"Point",[39,40],26.55597,41.67719,{"lat":40,"lon":39},[43],{"name":44,"role":27,"phone":45,"phoneExt":10,"email":29},"Alper Mengi","+90 5537 651 03 85",{"type":47,"investigatorFullName":44,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Associate Professor","100630436",false,"NCT07487649","Treatment Response in Patients With Medication-Overuse Headache","Factors Affecting Treatment Response in Patients With Medication-Overuse Headache Undergoing Greater Occipital Nerve Blockade","Inclusion Criteria:\n\n* Age between 18 and 65 years\n* Diagnosis of medication-overuse headache according to the International Classification of Headache Disorders, 3rd edition (ICHD-3)\n* Diagnosis of medication-overuse headache associated with the use of triptans or nonsteroidal anti-inflammatory drugs\n* Previous diagnosis of chronic migraine or chronic tension-type headache according to the ICHD-3 criteria\n\nExclusion Criteria:\n\n* History of severe head or neck trauma or previous neurosurgical intervention\n* Presence of a severe psychiatric disorder (e.g., severe depression, schizophrenia)\n* History of infectious disease, chronic inflammatory disease, or malignancy\n* Previous diagnosis of secondary headache\n* History of substance abuse\n* Pregnancy or breastfeeding\n* History of an additional neurological disorder (e.g., cerebrovascular disease, multiple sclerosis)\n* Difficulty with cooperation\n* Presence of a concomitant systemic disease that may affect quality of life (e.g., congestive heart failure, chronic kidney disease, chronic liver disease, pulmonary disease, uncontrolled diabetes, or peripheral vascular disease)","ALL","18 Years","65 Years",{"count":59,"type":60},70,"ESTIMATED","OBSERVATIONAL","The aim of this study to evaluate pre-injection patient-related factors that may influence treatment response in patients with medication-overuse headache who underwent ultrasound-guided greater occipital nerve block.",[64,65,66,67],"Medication-overuse Headache","Treatment","Headache","Greater Occipital Nerve Block","2026-03-17",{"date":70,"type":71},"2026-03-23","ACTUAL",{"date":68,"type":71},{"date":74,"type":60},"2026-05-30",{"name":5,"class":6},1]